drugset / Trial / NCT06846671
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Timeline
- Start
- 2025-04-10
- Primary completion
- 2028-05-15
- Completion
- 2030-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | — | Intravenous |
| Comparator | Idelalisib | Small molecule | — | Oral |
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Tacabrutideg | Unknown | — | Oral |
| Comparator | Venetoclax | Small molecule | — | Oral |